To compare the effect of sea buckthorn and silver sulfadiazine dressing on period of wound healing in patients with second-degree burns: A randomized triple-blind clinical trial.
Mehrdad AbdullahzadehSaeed ShafieePublished in: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (2021)
Burn injuries can be associated with the incidence of disability and death, yet their management remains a costly difficult problem. We conducted this clinical trial to evaluate the period of wound healing with sea buckthorn dressings for the second-degree burns and compare the results with 1% silver sulfadiazine (SSD) dressings. This randomized triple-blind clinical trial was conducted in a hospital in Isfahan, Iran. Fifty-five patients suffering second-degree burns were recruited through convenient sampling and randomly divided into two groups and treated with either sea buckthorn cream or 1% SSD. Wound dressings were done until complete wound healing was attained. The process of healing burns was monitored using the Bates-Jensen Wound Assessment Tool; complete healing was determined by using the standard burn healing checklist. It was deduced that the period of healing second-degree burns in the group treated with sea buckthorn cream was shorter than the group treated with 1% SSD (p < 0.001). The results demonstrated the greater clinical efficacy of sea buckthorn cream over 1% SSD for healing second-degree burns. It was concluded that using sea buckthorn dressing by reducing the period of wound healing can shorten the course of treatment of second-degree burns as well as reduce the burden of care in health care services.
Keyphrases
- wound healing
- clinical trial
- healthcare
- double blind
- open label
- phase ii
- newly diagnosed
- phase iii
- end stage renal disease
- gold nanoparticles
- primary care
- ejection fraction
- risk factors
- study protocol
- mental health
- multiple sclerosis
- palliative care
- emergency department
- peritoneal dialysis
- social media
- adverse drug
- health information
- replacement therapy